The goal of screening is to detect potential diseases or conditions before they occur while avoiding misdiagnosis and the over-and under-treatment it can cause. While Pap cytology has had a positive impact on HPV and cervical cancer screening over the past 50 years, it is resource-intensive and subject to misinterpretation and missed disease.
CINtec® PLUS Cytology is a triage test for cervical cancer screening, and the only test that uses dual-biomarker technology to simultaneously detect p16 and Ki-67 to provide a strong indicator of the presence of transforming HPV infections. CINtec® PLUS Cytology objectively identifies transforming HPV infections in women with abnormal Pap cytology results and HPV-positive cervical cancer screening results, allowing laboratory professionals to help physicians be certain they can recommend follow-up for women who will benefit most from colposcopy.
Unique dual-biomarker technology makes you certain about the presence of transforming HPV infection. CINtec® PLUS Cytology is the only test that uses dual-biomarker technology to simultaneously detect p16 and Ki-67 to provide a strong indicator of the presence of transforming HPV infections. Co-expression of p16 and Ki-67 in the same cell is strongly associated with established high-grade disease.
Additional information, from the same sample collected for HPV DNA or Pap screening, helps ensure women are not lost to follow-up
CINtec® PLUS Cytology outperforms Pap cytology as the triage test for HPV (+) screening results
An objective biomarker triage test for ASC-US and LSIL, abnormal Pap cytology screening results
CINtec® PLUS Cytology identifies underlying transforming HPV infections in women with abnormal Pap cytology results to send the women who will benefit most from colposcopy for follow-up testing.
* For HPV16/18+ triage, use in conjunction with the physician’s assessment of patient screening history, other risk factors, and professional guidelines to guide patient management
An objective biomarker triage test with high sensitivity and specificity
cobas® HPV DNA test with triage using CINtec® PLUS Cytology detects transforming HPV infections and helps avoid unnecessary colposcopy for women who do not need it immediately.
An objective biomarker test to help triage Pap negative/HPV (+) co-testing results
Improve management of women with Pap cytology negative/HPV (+) results: In co-testing, CINtec®PLUS Cytology provides immediate and actionable results to help reduce the number of women lost to follow-up testing.
HPV (+) triage
CINtec® PLUS Cytology outperforms Pap cytology as the triage test for HPV (+) screening results
Pap Cytology (-) HPV (+) triage
CINtec® PLUS Cytology can detect the cervical disease that Pap cytology misses
ASC-US cytology triage
CINtec® PLUS Cytology may reduce the number of women that require referral to colposcopy compared with HPV testing in the ASC-US population
LSIL cytology triace
Where the only current management option is colposcopy, CINtec® PLUS Cytology can detect those women where no colposcopic referral is needed
Younger women
Where transient HPV infections are more prevalent, CINtec® PLUS Cytology may reduce the number of unneeded colposcopy referrals
Currently, the CINtec® PLUS Cytology test is included in guidelines in Ecuador, France, Germany, Hong Kong, Portugal, South Africa, and Spain.
Unless otherwise indicated, all images of people are stock photos, posed by models.
